Showing results (1-10 of 27) with videos related to

Sort By:
Pageof 3
Drug Safety|September 3, 2009
Pharmacovigilance of biopharmaceuticals: challenges remainThijs J Giezen, Aukje K Mantel-Teeuwisse, Hubert G M Leufkens
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|December 6, 2021
Patients Retransitioning from Biosimilar TNFα Inhibitor to the Corresponding Originator After Initial Transitioning to the Biosimilar: A Systematic ReviewRosanne W Meijboom, Helga Gardarsdottir, Toine C G Egberts, et al.
Biologicals : Journal of the International Association of Biological Standardization|January 17, 2021
Comparison of consistency and complementarity of reporting biosimilar quality attributes between regulatory and scientific communities: An adalimumab case studyAli M Alsamil, Thijs J Giezen, Toine C Egberts, et al.
Pharmaceuticals (Basel, Switzerland)|March 6, 2021
Type and Extent of Information on (Potentially Critical) Quality Attributes Described in European Public Assessment Reports for Adalimumab BiosimilarsAli M Alsamil, Thijs J Giezen, Toine C Egberts, et al.
Drug Discovery Today|July 24, 2023
Post-approval quality-related regulatory actions for biopharmaceuticals approved in the European Union and the United States between 1995 and 2019Ali M Alsamil, Helga Gardarsdottir, Hubert G Leufkens, et al.
Clinical Pharmacology and Therapeutics|November 22, 2018
Identifiability of Biologicals in Adverse Drug Reaction Reports Received From European Clinical PracticeNiels S Vermeer, Thijs J Giezen, Sofia Zastavnik, et al.
Clinical Pharmacology and Therapeutics|September 2, 2021
Identifiability of Biologicals: An Analysis Using EudraVigilance, the European Union's Database of Reports of Suspected Adverse Drug ReactionsLuis Correia Pinheiro, Thijs J Giezen, Elena Wolff-Holz, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|May 31, 2022
Nature and timing of post-approval manufacturing changes of tumour necrosis factor α inhibitor products: A 20-year follow-up study of originators and biosimilarsAli M Alsamil, Thijs J Giezen, Toine C Egberts, et al.
British Journal of Clinical Pharmacology|May 15, 2024
Intranasal vitamin B12 administration in elderly patients: A randomized controlled comparison of two dosage regimensMonique P H Tillemans, Thijs J Giezen, Toine C G Egberts, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|October 27, 2021
Incidence of and Reasons and Determinants Associated with Retransitioning from Biosimilar Etanercept to Originator EtanerceptRosanne W Meijboom, Helga Gardarsdottir, Matthijs L Becker, et al.
Pageof 3